Cilnidipine

Cilnidipine is a fourth-generation dihydropyridine calcium channel blocker. It shares the vasodilating, blood-pressure-lowering action of the wider dihydropyridine family, but it is distinguished by a dual mechanism: in addition to the L-type calcium channels that all dihydropyridines target, it also blocks N-type calcium channels found on sympathetic nerve terminals.

The compound was patented in the 1980s and approved for medical use around the middle of the 1990s, having been developed in Japan. It is sold under brand names such as Atelec and Cilacar and is licensed across several Asian markets including Japan, China, India, Korea, and Nepal; it is not approved in the United States. More recently the molecule has drawn interest for possible use in conditions such as Raynaud's phenomenon.

Its principal use is essential hypertension. Large real-world post-marketing studies support its effectiveness and tolerability: the ACHIEVE-ONE study in patients with essential hypertension reported clear reductions in both clinic and home blood pressure, with the fall in heart rate greatest in those who started with higher pulse rates ^[2], and the CA-ATTEND surveillance study found that cilnidipine lowered blood pressure and was well tolerated even in post-stroke hypertensive patients ^[1]. A smaller randomized crossover study showed that it reduced twenty-four-hour blood pressure without raising heart rate and blunted the pressor response to cold stress, consistent with its effect on the sympathetic nervous system ^[3]. Its N-type blockade has also prompted research into possible protective effects on the kidney.

Cilnidipine is taken by mouth, usually once daily, and is dispensed as an oral tablet on prescription. Because it dilates both arterioles and venules, it is often described as producing less ankle swelling than some conventional dihydropyridine calcium blockers.

Cilnidipine is prescription only and is generally well tolerated. Possible effects include headache, dizziness, flushing, and palpitations, though palpitations and ankle swelling are less frequent than with amlodipine because of its N-type action. Low blood pressure and lightheadedness can occur, especially when standing quickly. It is used cautiously in advanced liver disease, since the liver clears it, and in severe aortic stenosis. Stopping it suddenly is not typically dangerous the way it is with beta blockers, but blood pressure may rebound. Its levels rise with strong CYP3A4 inhibitors and grapefruit juice. Safety data in pregnancy are limited, so it is generally avoided.

Cilnidipine is a dihydropyridine calcium channel blocker developed in Japan and introduced to the market there in the mid-1990s, reaching medical use around 1995 under brand names such as Atelec, with Cilacar among the names used elsewhere in Asia. It was designed as a fourth-generation dihydropyridine distinguished by a dual mechanism, adding blockade of N-type calcium channels on sympathetic nerve terminals to the L-type channel blockade shared by the whole class.

This second action, restraining the calcium-dependent release of norepinephrine, was intended to lower blood pressure while dampening the reflex increase in heart rate that can accompany conventional calcium antagonists. The drug has been marketed principally in Japan, India, and several other Asian countries rather than in Western markets. Interest in its N-type activity subsequently expanded into research on its effects on the kidney and the sympathetic nervous system.

Cilnidipine is regarded as a refined member of the dihydropyridine family, valued for combining effective blood-pressure control with a gentler impact on heart rate and a lower tendency to cause the ankle swelling common with older calcium blockers. Its defining N-type channel blockade, which curbs sympathetic nerve activity, has attracted particular attention for possible kidney-protective effects.

Clinical studies have reported that it can reduce urinary protein more effectively than the L-type-selective blocker amlodipine when added to renin-angiotensin system inhibitors in patients with chronic kidney disease, a finding that has bolstered its standing among nephrologists and hypertension specialists in the regions where it is used. Reviewers describe it as an effective and well-tolerated choice for mild to moderate essential hypertension, alone or in combination. Its evidence base, while favorable, is concentrated in Asian populations, reflecting its regional marketing.